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1. Introduction   
Even if the notion of refractory epilepsy is difficult to define precisely, it is widely admitted 
that it corresponds to the failure of two or more drugs and occurrence of one or more 
seizures per month over 18 months. Approximately 30 to 35% of epileptic patients will 
experience refractory epileptic periods in their lifetime despite maximal antiepileptic 
medications or they will suffer from serious side effects of their medical treatments. Indeed 
neurosurgical resection procedures including cortectomies and temporal lobe surgeries may 
result in a dramatic improvement of seizure frequency in selected patients, but these 
procedures carry a non-negligible rate of potentially serious risks with a mortality rate 
reaching more than 3% in some centers.  
Another surgical option with less risks and reversible action for these patients is represented 
by vagus nerve stimulation (VNS), mainly in those patients that are not candidates for a 
surgical resection. VNS consists in the chronic and intermittent stimulation of the tenth 
cranial nerve  (vagus nerve) in its extracranial cervical segment. Even if the pathophysiology 
of VNS in the treatment of refractory epilepsy is not yet clearly understood, the procedure 
has shown its efficacy in terms of quality of life improvement since the end of the 1990’s in 
many types of epilepsy. The United States Food and Drug Administration (FDA) have 
approved the technique in 1997 as an adjunct to pharmacotherapy for adults and 
adolescents (more than 12 years). The VNS device has been developed by Cyberonics, Inc 
(Houston, TX).  
In this review, we describe the state of the art of VNS including technical considerations, 
possible mechanisms of action, main clinical studies and future trends.      
2. Technical considerations 
Initially, the FDA approved the use of the VNS system as an adjunctive therapy in adults 
and adolescents with partial onset seizures, but lately extended the use of the VNS device 
for children and in seizures other than partial onset. The placement of the device is 
performed either by neurosurgeons or ENT surgeons after rigorous selection of patients by 
specialized neurologists. The surgical procedure is simple but requires special skills to 
identify the vagus nerve in the neck and carries complications and potentially lethal risks 
(Santos 2004).   
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2.1 Vagus nerve anatomy and VNS device 
The vagus nerve or tenth cranial nerve is composed for up to 80% of its fibers by afferent 
ones originating from the viscera while 20% of its fibers are efferent and dedicated to the 
innervation of the larynx but also to the parasympathetic management of the heart, lungs 
and digestive tract. During VNS, the procedure will involve the mid paralaryngeal 
skeleton portion of the vagus nerve just behind the carotid sheath between and posterior 
to the common carotid artery and internal jugular vein. It is important to avoid using the 
device on the vagus nerve before the birth of its cardiac superior and inferior branches.    
The VNS device consists in a generator and a lead. This generator delivers an intermittent 
electrical stimulation with precise and adjustable characteristics including output current, 
pulse width, frequency and stimulation on and off time. These parameters are adjusted 
postoperatively depending on therapeutic response and clinical tolerance. Initially the 
output current is usually set to zero mA for the first 2 to 3 postoperative weeks. Normalized 
parameters have been found to be the more effective at the beginning of the adjustments 
and have been found to be the more valuable in double-blind controlled studies: 500 µs 
pulse width, 30 Hz signal frequency, 30 seconds on-time and 5 minutes off-time. Further 
incremental increases in output current may be necessary depending on therapeutic effects. 
A hand-held magnet is given to patients with VNS (or to their caregivers) to activate directly 
the generator trans-cutaneously in case of auras or partial fits in order to reduce the 
incidence of severe seizures.  
2.2 Surgical procedure 
Many variations of VNS placement techniques have been described until now. In the 
majority of cases, the left vagus nerve has been used because of potentially higher risks of 
bradycardia and cardiac rhythm anomalies with the right vagus nerve. There is no clear 
evidence for this last data, resulting in the placement of VNS devices on either side.  
Preoperative consent must be obtained and signed either by the patient or his guardian, 
after explaining attending risks and benefits of the procedure. The patient should be 
informed of the scarring lines in the neck and the preaxillary region as well as the voice 
changes possibilities during the stimulation cycles of the device. The patient and/or 
guardian should also be informed of the limited duration of the battery that will have to be 
replaced within a 7 to 10 years period depending on parameters set.  
Under general anaesthesia and orotracheal intubation, the patient is placed supine with the 
head turned to the right side for a left-sided VNS placement. A 3 cm transverse incision is 
performed at the level of the cricothyroid membrane parallel to the anterior edge of the 
sternocleidomastoid muscle. This latter is dissected medially until one reaches the common 
carotid artery and the internal jugular vein. The vagus nerve is usually found on the 
posterior wall of the carotid sheath. Nearly 25 to 35 mm of the nerve are carefully dissected 
without any tearing or injury to the nerve. The vagus nerve adventitia and vasa nervorum 
must be preserved. The choice of the lead model is adapted to the nerve diameter before 
being delicately placed around the vagus nerve.  An ipsilateral infraclavicular subcutaneous 
pocket is dissected to receive the generator, while the lead connector is tunnelled 
subcutaneously and connected to the helical electrodes. Proper placement of helical lead 
(distal to superior laryngeal nerve and cardiac cervical branches) and electrodes orientation 
is mandatory before peroperative testing of the device. The surgical and anaesthetic teams 
must be aware of the potentially serious cardiac rhythm anomalies that may occur during 
VNS testing including cardiac arrest (2-3%). Various complications and side effects are 
actually very well documented (Table 1) (Spuck et al. 2010). 
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Complications 
Infection (3-8%) requiring generally device 
explantation 
Vocal cord paralysis 0,7% (transient or 
permanent) that can be avoided with careful 
dissection of the nerve and rigorous choice of 
the size of the lead  
Hematoma, seroma 
Nausea and vomiting  
Paresthesia  
Bradycardia 
Cardiac arrest (1/400 to 1/800) 
Device malfunction 
Lead fracture 
Pneumothorax 
Facial paralysis 
Horner’s syndrome 
Stimulation cycle related side effects 
Coughing 
Laryngismus 
Voice alteration 
Local strap sensation 
Neck muscle contractures and spasms 
Dyspnea 
Dyspepsia 
Dysphagia 
Local pain 
Table 1. Complications and adverse effects of VNS 
3. Rationale of VNS in refractory epilepsy 
Pathophysiology and mechanisms of action of VNS in refractory epilepsy are still subject 
to discussions and debates (Barnes et al. 2003). As already said, vagus nerve is composed 
of 80 % of afferent fibers and 20 % of efferent ones. The afferent fibers of the vagus nerve 
are known to originate from nodose and jugular ganglia to innervate both nuclei tractus 
solitarius and projecting to different regions involved in epileptic activity. This afferent 
contingent of fibers is mainly composed of small diameter unmyelinated fibers (C) but 
also large diameter myelinated ones (A and B). It is hypothesized that the chronic and 
intermittent stimulation of these afferent fibers of vagus nerve are involved in the anti-
epileptic effect of VNS, while the exact mechanism is still unclear. Initially, C fibers were 
thought to be responsible of this effect in animals, but human studies did not comfort this 
hypothesis. Elsewhere, it has been demonstrated that various thalamic nuclei contain 
thalamocortical relay neurons with large projections on cerebral cortex. VNS may 
therefore induce changes in the metabolism of these thalamic nuclei by the mean of trans-
synaptic neurotransmission modulation, as shown by PET scan. This latter demonstrated 
an increase of the blood flow in both thalami secondary to VNS that correlates with anti-
epileptic effect.  
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Many studies of neurochemical concentrations of aminoacids and neurotransmitters in CSF 
and brain samples during VNS have shown variations of ethanolamine in specific locations 
such as locus coeruleus, a region directly involved in seizure propagation. VNS is also 
involved in long stimulation of NTS, parabrachial nucleus, paraventricular nucleus of the 
hypothalamus, ventral bed nucleus of the stria terminalis, dorsal raphe nucleus and 
cingulated cortex. CSF aspartate level, an excitatory neurotransmitter, has also been shown 
to decrease significantly in chronic VNS.  
On an electrical point of view, EEG studies have proven cortical synchronization or 
desynchronization depending on stimulation frequency and intensity, explaining the 
importance of rigorous stimulation parameters in VNS (Marrosu 2005).  
4. Clinical outcome 
Significant clinical data supports that chronic and intermittent VNS is actually considered as 
a valuable treatment of refractory epilepsy (Table 2). It is mandatory to present this 
therapeutic modality to patients and their family not as a curative treatment but as an 
adjunct to antiepileptic drugs. Additionally to the significant decrease of epilepsy frequency 
and severity according to Engel postoperative assessment (Table 3), VNS reduces 
antiepileptic drugs toxicity but also the frequency of epilepsy-related hospitalization which 
is a great financial issue.  Efficacy and clinical tolerance of VNS may require a long period of 
parameters adjustments. After promising preliminary results of pilot studies in the 1990’s, 
multicenter double-blinded randomized trials in adults with refractory epilepsy confirmed 
the efficacy of VNS in terms of reduction of frequency, severity and duration of seizures. It 
is now admitted that this efficacy may require several months or even years of VNS to be 
obvious. Patients are considered as responders to VNS if they experience more than 50 % of 
reduction in seizure frequency.  
 
Series N 
Follow-up 
(months) 
Mean age 
(years) 
 Change in seizure 
frequency from baseline 
Salinsky et al (1996) 100 10-12 33,3 -32 % 
Handforth et al (1998) 94 3-4 32 -27,9 % 
Scherrmann et al (2001) 95 16 34,9 -30 % 
Labar (2004) 269 12 32 -58 % 
Saneto et al (2006) 43 18 8 -84 % 
De Herdt et al (2007) 138 44 30 -51 % 
Amar et al (2008) 3822 24 26 -66,7 % 
Sherman et al (2008) 34 12 12,3 -51,2 % 
Elliot et al (2011) 65 124,8 30 -76,3 % 
Table 2. Selected published data on the efficacy of VNS in refractory epilepsy 
In long-term follow-up studies, VNS has proven to have an excellent tolerability with 
continuation rates reaching 70 % at three years. These studies confirmed also the existence of 
an incremental and cumulative seizure suppression effect of VNS over time as a possible result 
of the optimization of parameters adjustments and/or antiepileptic medications changes.  
Another benefit of VNS is the marked improvement of the overall quality of life in these 
patients, probably mediated by the reduction of antiepileptic drugs toxicity and treatment 
costs or epilepsy-related hospitalization reduction. 
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In the paediatric population, studies are less common even if they showed obviously better 
results of VNS on refractory epilepsy than adults, with reduction of 50 to 90% in seizure 
frequency at one-year follow-up. VNS have also shown evident efficacy in Lennox-Gastaud 
syndrome and tuberous sclerosis complex.   
 
Class I 
No disabling seizures 
A – Completely seizure-free since surgery 
B – Non-disabling simple partial seizures only 
C – Some disabling seizures after surgery but free of disabling 
seizures for at least 2 years 
D – Generalized convulsion with antiepileptic drug 
withdrawal only 
Class II 
Rare disabling seizures 
A – Initially free of disabling seizures but has rare disabling 
seizures now 
B – Rare disabling seizures since surgery 
C – More than rare disabling seizures since surgery but rare 
seizures for at least 2 years 
D – Nocturnal seizures only 
Class III 
Worthwhile improvement
A – Worthwhile seizure reduction 
B – Prolonged seizure-free intervals but less than 2 years 
Class IV 
No worthwhile 
improvement 
A – Significant seizure reduction 
B – No appreciable change in seizure frequency 
C – Seizures are more frequent or worse 
Table 3. Engel classification of postoperative outcome 
5. Conclusion 
Chronic and intermittent vagus nerve stimulation is actually considered as a safe and very 
effective complementary treatment for patients with refractory epilepsy. Initially indicated 
exclusively in adults, the technique is currently diffusing in paediatric patients. A 
cumulative incremental effectiveness of VNS has been demonstrated with an increasing 
efficacy over the years of stimulation. VNS is also considered as a very valuable technique 
for the improvement of the overall quality of life in patients with refractory epilepsy. VNS is 
moreover being used in a variety of other pathologies including major depression, 
Alzheimer disease, congestive heart failure or even bowel inflammatory disorders.  
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